Capturing the Magic Bullet: Pharmacokinetic Principles and Modeling of Antibody-Drug Conjugates
Author:
- 6 August 2020
- journal article
- review article
- Published by Springer Nature in The AAPS Journal
- Vol. 22 (5) , 1-13
Abstract
Over the past two decades, antibody-drug conjugates (ADCs) have emerged as a promising class of drugs for cancer therapy and have expanded to nononcology fKeywords
This publication has 66 references indexed in Scilit:
- Implications of receptor-mediated endocytosis and intracellular trafficking dynamics in the development of antibody drug conjugatesmAbs, 2013
- Impact of Drug Conjugation on Pharmacokinetics and Tissue Distribution of Anti-STEAP1 Antibody–Drug Conjugates in RatsBioconjugate Chemistry, 2011
- Design of Antibody−Maytansinoid Conjugates Allows for Efficient Detoxification via Liver MetabolismBioconjugate Chemistry, 2011
- Brentuximab Vedotin (SGN-35) for Relapsed CD30-Positive LymphomasNew England Journal of Medicine, 2010
- Gender-specific differences in bladder cancer: A retrospective analysisGender Medicine, 2008
- Paul Ehrlich's magic bullet concept: 100 years of progressNature Reviews Cancer, 2008
- A two-tiered physiologically based model for dually labeled single-chain Fv-Fc antibody fragmentsMolecular Cancer Therapeutics, 2006
- Effects of Drug Loading on the Antitumor Activity of a Monoclonal Antibody Drug ConjugateClinical Cancer Research, 2004
- Pharmacokinetics and Biodistribution of the Antitumor Immunoconjugate, Cantuzumab Mertansine (huC242-DM1), and Its Two Components in MiceThe Journal of Pharmacology and Experimental Therapeutics, 2004
- Pharmacokinetics of Gemtuzumab Ozogamicin, an Antibody‐Targeted Chemotherapy Agent for the Treatment of Patients with Acute Myeloid Leukemia in First RelapseThe Journal of Clinical Pharmacology, 2001